[go: up one dir, main page]

CL2007001665A1 - Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease. - Google Patents

Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.

Info

Publication number
CL2007001665A1
CL2007001665A1 CL2007001665A CL2007001665A CL2007001665A1 CL 2007001665 A1 CL2007001665 A1 CL 2007001665A1 CL 2007001665 A CL2007001665 A CL 2007001665A CL 2007001665 A CL2007001665 A CL 2007001665A CL 2007001665 A1 CL2007001665 A1 CL 2007001665A1
Authority
CL
Chile
Prior art keywords
understands
antibody
fragment
treat
protein
Prior art date
Application number
CL2007001665A
Other languages
Spanish (es)
Inventor
Masakazu Hasegawa
Hidetomo Kitamura
Hideki Adachi
Keiko Kasutani
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38801569&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2007001665(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CL2007001665A1 publication Critical patent/CL2007001665A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Pain & Pain Management (AREA)
  • Cell Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Anticuerpo o fragmento del mismo con actividad neutralizante de la proteína nr 10; agente que lo comprende; y su uso para prevenir o tratar una enfermedad inflamatoria.Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.

CL2007001665A 2006-06-08 2007-06-08 Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease. CL2007001665A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2006160096 2006-06-08

Publications (1)

Publication Number Publication Date
CL2007001665A1 true CL2007001665A1 (en) 2008-01-18

Family

ID=38801569

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2007001665A CL2007001665A1 (en) 2006-06-08 2007-06-08 Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.

Country Status (25)

Country Link
US (2) US9028821B2 (en)
EP (2) EP2047863B1 (en)
JP (1) JP5043008B2 (en)
KR (3) KR101557603B1 (en)
CN (2) CN103272232B (en)
AR (1) AR061317A1 (en)
AU (1) AU2007255753B2 (en)
BR (1) BRPI0712426B1 (en)
CA (1) CA2654623C (en)
CL (1) CL2007001665A1 (en)
DK (1) DK2047863T3 (en)
ES (2) ES2544888T3 (en)
IL (1) IL195361A0 (en)
MX (1) MX2008015568A (en)
MY (1) MY157796A (en)
NO (1) NO344849B1 (en)
NZ (1) NZ572888A (en)
PE (1) PE20080333A1 (en)
PL (1) PL2047863T3 (en)
PT (1) PT2047863E (en)
RU (1) RU2511406C2 (en)
SI (1) SI2047863T1 (en)
TW (1) TWI419703B (en)
UA (1) UA100116C2 (en)
WO (1) WO2007142325A1 (en)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2339843T3 (en) * 1999-06-02 2010-05-26 Chugai Seiyaku Kabushiki Kaisha PROTEIN RECEIVING HEMATOPOYETINA NOVEDOSA, NR10.
WO2001023556A1 (en) * 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2006106905A1 (en) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha Process for production of polypeptide by regulation of assembly
WO2007114319A1 (en) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
US9670269B2 (en) 2006-03-31 2017-06-06 Chugai Seiyaku Kabushiki Kaisha Methods of modifying antibodies for purification of bispecific antibodies
JP5043008B2 (en) 2006-06-08 2012-10-10 中外製薬株式会社 Preventive or therapeutic agent for inflammatory diseases
CN101874041B (en) 2007-09-26 2013-06-19 中外制药株式会社 Modified antibody constant region
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TWI548418B (en) 2007-12-05 2016-09-11 Chugai Pharmaceutical Co Ltd Anti-NR10 / IL-31RA antibody and its use
WO2009072598A1 (en) * 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
KR101620539B1 (en) * 2007-12-21 2016-05-13 메디뮨 리미티드 -4 -4 -173binding members for interleukin-4 receptor alpha il-4r-173
EP2708559B1 (en) * 2008-04-11 2018-03-28 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
TWI440469B (en) 2008-09-26 2014-06-11 Chugai Pharmaceutical Co Ltd Improved antibody molecules
KR20160062207A (en) * 2008-12-05 2016-06-01 추가이 세이야쿠 가부시키가이샤 Anti-NR10 antibody and use thereof
JP5139517B2 (en) * 2008-12-05 2013-02-06 中外製薬株式会社 Anti-NR10 antibody and use thereof
JP2010210772A (en) * 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device
WO2010107110A1 (en) 2009-03-19 2010-09-23 中外製薬株式会社 Antibody constant region variant
EP3674317B1 (en) 2009-03-19 2024-12-11 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
HRP20180421T1 (en) 2010-11-17 2018-04-20 Chugai Seiyaku Kabushiki Kaisha Multi-specific antigen-binding molecule having alternative function to function of blood coagulation factor viii
TWI654204B (en) 2010-11-30 2019-03-21 中外製藥股份有限公司 Antibody with calcium-dependent antigen binding ability
WO2012115241A1 (en) 2011-02-25 2012-08-30 中外製薬株式会社 Fcγriib-specific fc antibody
TW201817744A (en) 2011-09-30 2018-05-16 日商中外製藥股份有限公司 Therapeutic antigen-binding molecule having an FcRn binding domain that promotes antigen clearance
WO2013047748A1 (en) 2011-09-30 2013-04-04 中外製薬株式会社 Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
ES2692657T3 (en) 2013-05-30 2018-12-04 Kiniksa Pharmaceuticals, Ltd. Proteins binding to oncastatin receptor antigen
RU2730594C2 (en) 2013-09-27 2020-08-24 Чугаи Сейяку Кабусики Кайся Method of producing a polypeptide heteromultiters
MA40764A (en) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd THERAPEUTIC AGENT INDUCING CYTOTOXICITY
ES2899894T3 (en) 2014-12-19 2022-03-15 Chugai Pharmaceutical Co Ltd Anti-C5 antibodies and methods of use
CA2963760A1 (en) 2014-12-19 2016-06-23 Yoshinao Ruike Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MX2017008978A (en) 2015-02-05 2017-10-25 Chugai Pharmaceutical Co Ltd Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof.
ES2967627T3 (en) 2015-02-27 2024-05-03 Chugai Pharmaceutical Co Ltd Composition to treat diseases related to IL-6
HUE072989T2 (en) 2015-04-14 2025-12-28 Chugai Pharmaceutical Co Ltd Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing il-31 antagonist as active ingredient
AU2016248786B2 (en) 2015-04-14 2022-01-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for prevention and/or treatment of atopic dermatitis containing lL-31 antagonist as active ingredient
WO2017110981A1 (en) 2015-12-25 2017-06-29 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
SG11201803989WA (en) 2015-12-28 2018-06-28 Chugai Pharmaceutical Co Ltd Method for promoting efficiency of purification of fc region-containing polypeptide
MA44780A (en) 2016-04-28 2019-03-06 Chugai Pharmaceutical Co Ltd PREPARATION CONTAINING AN ANTIBODY
TWI831965B (en) 2016-08-05 2024-02-11 日商中外製藥股份有限公司 Compositions for the treatment or prevention of IL-8 related diseases
US11608374B2 (en) 2017-01-30 2023-03-21 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
EP3620531A4 (en) 2017-05-02 2021-03-17 National Center of Neurology and Psychiatry METHOD FOR PREDICTING AND EVALUATING A THERAPEUTIC EFFECT IN DISEASES ASSOCIATED WITH IL-6 AND NEUTROPHILS
MA50534A (en) 2017-11-01 2020-09-09 Chugai Pharmaceutical Co Ltd ANTIBODY VARIANT AND ISOFORM WITH REDUCED BIOLOGICAL ACTIVITY
BR112022006590A2 (en) 2019-11-20 2022-06-28 Chugai Pharmaceutical Co Ltd PREPARATION CONTAINING ANTIBODIES
KR102269716B1 (en) 2020-09-01 2021-06-28 추가이 세이야쿠 가부시키가이샤 A pharmaceutical composition for the prevention and/or treatment of dialysis pruritus comprising an IL-31 antagonist as an active ingredient
CN112552396B (en) * 2020-12-30 2022-07-12 河南中泽生物工程有限公司 anti-African swine fever virus p54 protein monoclonal antibody, preparation method and application
TW202340249A (en) 2021-12-22 2023-10-16 日商中外製藥股份有限公司 Antibody variant with reduced biological activity

Family Cites Families (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US5156840A (en) 1982-03-09 1992-10-20 Cytogen Corporation Amine-containing porphyrin derivatives
JPS58201994A (en) 1982-05-21 1983-11-25 Hideaki Hagiwara Method for producing antigen-specific human immunoglobulin
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5057313A (en) 1986-02-25 1991-10-15 The Center For Molecular Medicine And Immunology Diagnostic and therapeutic antibody conjugates
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
JPS63149900A (en) 1986-12-15 1988-06-22 Toshiba Corp Semiconductor memory
JP2898064B2 (en) 1989-08-03 1999-05-31 忠三 岸本 Human gp130 protein
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
GB9016440D0 (en) 1990-07-26 1990-09-12 Elopak Systems A laminate
DE69133476T2 (en) 1990-08-29 2006-01-05 GenPharm International, Inc., Palo Alto Transgenic mice capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
ES2341666T3 (en) 1991-12-02 2010-06-24 Medimmune Limited PRODUCTION OF AUTHORTIC BODIES OF REPERTORIES OF ANTIQUE RPOS SEGMENTS EXPRESSED ON THE FAGOS SURFACE.
DE69333823T2 (en) 1992-03-24 2006-05-04 Cambridge Antibody Technology Ltd., Melbourn METHOD FOR PRODUCING MEMBERS OF SPECIFIC BINDING SAVINGS
JPH07509137A (en) 1992-07-24 1995-10-12 セル　ジェネシス，インク． Production of xenoantibodies
BR9204244A (en) 1992-10-26 1994-05-03 Cofap Gray cast iron
EP0671951A4 (en) 1992-12-01 1997-05-21 Protein Design Labs Inc HUMANIZED ANTIBODIES THAT REACT WITH 1-SELECTECT.
CA2161351C (en) 1993-04-26 2010-12-21 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
GB9313509D0 (en) 1993-06-30 1993-08-11 Medical Res Council Chemisynthetic libraries
EP0731842A1 (en) 1993-12-03 1996-09-18 Medical Research Council Recombinant binding proteins and peptides
US5783672A (en) 1994-05-26 1998-07-21 Immunex Corporation Receptor for oncostatin M
WO1996002576A1 (en) 1994-07-13 1996-02-01 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin-8
US5876950A (en) 1995-01-26 1999-03-02 Bristol-Myers Squibb Company Monoclonal antibodies specific for different epitopes of human GP39 and methods for their use in diagnosis and therapy
FR2729855A1 (en) 1995-01-26 1996-08-02 Oreal USE OF A CGRP ANTAGONIST IN A COSMETIC, PHARMACEUTICAL OR DERMATOLOGICAL COMPOSITION AND COMPOSITION OBTAINED
ATE390933T1 (en) 1995-04-27 2008-04-15 Amgen Fremont Inc HUMAN ANTIBODIES AGAINST IL-8 DERIVED FROM IMMUNIZED XENOMICES
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
AUPN481295A0 (en) 1995-08-16 1995-09-07 Medvet Science Pty. Ltd. Agonists of haemopoietic growth factors
WO1997010354A1 (en) 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. ANTIBODY AGAINTS α-CHAIN OF HUMAN INTERLEUKIN 5 RECEPTOR
AUPN564195A0 (en) 1995-09-26 1995-10-19 Walter And Eliza Hall Institute Of Medical Research, The A novel haemopoietin receptor and genetic sequences encoding same
DE69638050D1 (en) 1995-10-23 2009-11-19 Zenyth Operations Pty Ltd HEMOPOIETIN RECEPTOR AND FORMING GENETIC SEQUENCES
US6642360B2 (en) 1997-12-03 2003-11-04 Genentech, Inc. Secreted polypeptides that stimulate release of proteoglycans from cartilage
CN1241944A (en) 1996-12-05 2000-01-19 乔治敦大学 Extracts of salvia species having antiviral activity
FR2761994B1 (en) 1997-04-11 1999-06-18 Centre Nat Rech Scient PREPARATION OF MEMBRANE RECEPTORS FROM EXTRACELLULAR BACULOVIRUSES
JPH11101542A (en) 1997-09-29 1999-04-13 Sanyo Electric Co Ltd Refrigerator
US6747137B1 (en) 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
DE69929183T2 (en) 1998-04-30 2006-08-24 Tanox, Inc., Houston G-CSF RECEPTOR AGONIST ANTIBODIES AND SCREENING METHOD THEREFOR
FR2780062B1 (en) 1998-06-17 2000-07-28 Rhone Poulenc Rorer Sa MONOCLONAL ANTIBODIES DIRECTED AGAINST G3BP PROTEIN, AND USES THEREOF
WO1999067290A1 (en) 1998-06-24 1999-12-29 Chugai Research Institute For Molecular Medicine, Inc. Novel hemopoietin receptor proteins
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
SI1181366T2 (en) 1999-06-01 2013-10-30 Merck Sharp & Dohme Corp. Mammalian receptor proteins; related reagents and methods
US20030082734A1 (en) 1999-06-01 2003-05-01 Dowling Lynette M. Mammalian receptor proteins; related reagents and methods
ES2339843T3 (en) 1999-06-02 2010-05-26 Chugai Seiyaku Kabushiki Kaisha PROTEIN RECEIVING HEMATOPOYETINA NOVEDOSA, NR10.
WO2001023556A1 (en) 1999-09-27 2001-04-05 Chugai Seiyaku Kabushiki Kaisha Novel hemopoietin receptor protein, nr12
JP5073909B2 (en) 2000-05-10 2012-11-14 メルク・シャープ・アンド・ドーム・コーポレーション Mammalian receptor proteins; related reagents and methods
CN1326880A (en) 2000-06-06 2001-12-19 周伟中 Railway station with double layer platform
US20030096339A1 (en) * 2000-06-26 2003-05-22 Sprecher Cindy A. Cytokine receptor zcytor17
ES2593002T3 (en) 2000-06-26 2016-12-05 Zymogenetics, Inc. ZCYTOR17 cytokine receptor
JP2005507632A (en) 2000-10-06 2005-03-24 イミュネックス・コーポレーション Hematopoietin receptor, HPR1 and HPR2
WO2002077230A1 (en) * 2001-03-26 2002-10-03 Chugai Seiyaku Kabushiki Kaisha Nr10 splicing variants
ATE412013T1 (en) 2001-04-05 2008-11-15 Immuno Biological Lab Co Ltd ANTI-OSTEOPONTIN ANTIBODIES AND USE THEREOF
EP1961811B1 (en) 2002-01-18 2010-08-25 ZymoGenetics, Inc. Cytokine ligand for the treatment of asthma and airway hyper-responsiveness
EP2338910B1 (en) 2002-01-18 2015-07-08 ZymoGenetics, Inc. Cytokine receptor Zcytor17 multimers
DE60327608D1 (en) 2002-02-25 2009-06-25 Genentech Inc NEW TYPE 1 CYTOKIN RECEPTOR GLM-R
US7579000B2 (en) 2002-05-01 2009-08-25 Bayer Schering Pharma Ag Tissue factor targeted antibodies as anticoagulants
AU2003225255B2 (en) 2002-05-01 2008-07-31 Bayer Schering Pharma Aktiengesellschaft Novel tissue factor targeted antibodies as anticoagulants
TW200407335A (en) 2002-07-22 2004-05-16 Chugai Pharmaceutical Co Ltd Non-neutralizing antibody to inhibit the inactivation of activated protein C
KR100499989B1 (en) 2002-12-27 2005-07-07 네오바이오다임 주식회사 Monoclonal antibody against asialo α1-acid glycoprotein, immunochromatographic strip comprising the monoclonal antibody, and method for diagnosing liver diseases using the immunochromatographic strip
US9259459B2 (en) * 2003-01-31 2016-02-16 Celldex Therapeutics Inc. Antibody vaccine conjugates and uses therefor
US20040223970A1 (en) 2003-02-28 2004-11-11 Daniel Afar Antibodies against SLC15A2 and uses thereof
CA2517926A1 (en) 2003-03-04 2004-10-28 Alexion Pharmaceuticals, Inc. Method of treating autoimmune disease by inducing antigen presentation by tolerance inducing antigen presenting cells
CA2519057A1 (en) 2003-03-24 2004-10-07 Zymogenetics, Inc. Anti-il-20 antibodies and binding partners and methods of using in inflammation
JP5452835B2 (en) 2003-07-15 2014-03-26 中外製薬株式会社 Production of IgM by transformed cells and its quantification method
EP1773391A4 (en) 2004-06-25 2009-01-21 Medimmune Inc Increasing the production of recombinant antibodies in mammalian cells by site-directed mutagenesis
EP1671642A1 (en) 2004-12-15 2006-06-21 Universite D'angers Compositions comprising (ant)agonists of oncostatin M (OSM), IL-31 and IFN-gamma for modulating keratinocyte migration and functions via a receptor containing OSMRbeta as a subunit, and applications thereof.
EP3026063A1 (en) 2004-12-28 2016-06-01 Innate Pharma S.A. Monoclonal antibodies against nkg2a
EP1848737B1 (en) 2005-01-28 2016-05-18 ZymoGenetics, Inc. Homogeneous preparations of il-31
MX2007009718A (en) 2005-02-14 2007-09-26 Zymogenetics Inc Methods of treating skin disorders using an il-31ra antagonist.
AU2006214325B2 (en) 2005-02-14 2012-04-05 National Jewish Medical And Research Center Methods of treating diseases which are mediated by cutaneous lymphocyte antigen positive cells
PE20061323A1 (en) 2005-04-29 2007-02-09 Rinat Neuroscience Corp ANTIBODIES TARGETED AGAINST AMYLOID BETA PEPTIDE AND METHODS USING THEM
US8003108B2 (en) 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP5065253B2 (en) 2005-05-06 2012-10-31 ザイモジェネティクス， インコーポレイテッド IL-31 monoclonal antibody and method of use thereof
WO2007143231A2 (en) * 2006-01-10 2007-12-13 Zymogenetics, Inc. Methods of treating pain and inflammation in neuronal tissue using il-31 antagonists
WO2006132341A1 (en) 2005-06-10 2006-12-14 Chugai Seiyaku Kabushiki Kaisha sc(Fv)2 SITE-DIRECTED MUTANT
BRPI0707126A2 (en) 2006-01-12 2011-04-19 Alexion Pharma Inc ox-2 / cd200 antibodies and use of these
EP2004688B2 (en) 2006-03-23 2014-03-05 BioArtic Neuroscience AB Improved protofibril selective antibodies and the use thereof
JP5043008B2 (en) 2006-06-08 2012-10-10 中外製薬株式会社 Preventive or therapeutic agent for inflammatory diseases
US7858756B2 (en) 2006-06-15 2010-12-28 The Board Of Trustees Of The University Of Arkansas Monoclonal antibodies that selectively recognize methamphetamine and methamphetamine like compounds
EP2069404B1 (en) 2007-02-14 2011-01-05 Vaccinex, Inc. Humanized anti-cd100 antibodies
DK2059534T3 (en) 2007-02-23 2012-08-06 Merck Sharp & Dohme REPLACED ANTI-IL-23P19 ANTIBODIES
WO2008114733A1 (en) 2007-03-16 2008-09-25 Kyowa Hakko Kirin Co., Ltd. Anti-claudin-4 antibody
GB0708002D0 (en) 2007-04-25 2007-06-06 Univ Sheffield Antibodies
PE20140132A1 (en) 2007-09-26 2014-02-14 Chugai Pharmaceutical Co Ltd IL-6 ANTI-RECEPTOR ANTIBODY
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
CN101874041B (en) 2007-09-26 2013-06-19 中外制药株式会社 Modified antibody constant region
TWI548418B (en) 2007-12-05 2016-09-11 Chugai Pharmaceutical Co Ltd Anti-NR10 / IL-31RA antibody and its use
WO2009072598A1 (en) 2007-12-05 2009-06-11 Chugai Seiyaku Kabushiki Kaisha Therapeutic agent for pruritus
JP2010210772A (en) 2009-03-13 2010-09-24 Dainippon Screen Mfg Co Ltd Method of manufacturing liquid crystal display device

Also Published As

Publication number Publication date
NO20090093L (en) 2009-03-09
CN103272232B (en) 2018-07-24
JP5043008B2 (en) 2012-10-10
BRPI0712426A2 (en) 2012-07-17
KR20150091545A (en) 2015-08-11
CA2654623C (en) 2016-07-26
AU2007255753A1 (en) 2007-12-13
CA2654623A1 (en) 2007-12-13
US9028821B2 (en) 2015-05-12
NO344849B1 (en) 2020-06-02
BRPI0712426B1 (en) 2021-10-26
US20100055092A1 (en) 2010-03-04
KR101557603B1 (en) 2015-10-06
US20150315280A1 (en) 2015-11-05
IL195361A0 (en) 2011-08-01
PL2047863T3 (en) 2014-01-31
TW200810778A (en) 2008-03-01
AU2007255753B2 (en) 2013-01-17
RU2511406C2 (en) 2014-04-10
DK2047863T3 (en) 2013-09-16
EP2047863A1 (en) 2009-04-15
CN101500608A (en) 2009-08-05
ES2544888T3 (en) 2015-09-04
MX2008015568A (en) 2009-01-13
KR20090024243A (en) 2009-03-06
CN103272232A (en) 2013-09-04
EP2047863B1 (en) 2013-07-31
US9745378B2 (en) 2017-08-29
KR20140097495A (en) 2014-08-06
EP2047863A4 (en) 2009-12-09
WO2007142325A1 (en) 2007-12-13
MY157796A (en) 2016-07-29
ES2429407T3 (en) 2013-11-14
EP2371393B1 (en) 2015-08-05
NZ572888A (en) 2012-02-24
JPWO2007142325A1 (en) 2009-10-29
TWI419703B (en) 2013-12-21
SI2047863T1 (en) 2013-11-29
UA100116C2 (en) 2012-11-26
PE20080333A1 (en) 2008-06-15
PT2047863E (en) 2013-10-21
RU2008152827A (en) 2010-07-20
AR061317A1 (en) 2008-08-20
EP2371393A1 (en) 2011-10-05

Similar Documents

Publication Publication Date Title
CL2007001665A1 (en) Antibody or fragment thereof with neutralizing activity of protein nr 10; agent who understands it; and its use to prevent or treat an inflammatory disease.
CY1123030T1 (en) MATERIALS AND METHODS FOR TREATING OR PREVENTING HER-3 RELATED DISEASES
CR10347A (en) ANTIBODIES AGAINST PEPTIDOB-AMILOID
CY1118760T1 (en) MODIFIED ANTIBODIES AGAINST IL-23
BRPI0906478B8 (en) anti-nr10 antibody, its use and pharmaceutical composition comprising it
CL2013003214A1 (en) Stable formulation comprising at least one monoclonal antibody that specifically binds to pcsk9, a buffer, a surfactant and at least one stabilizer; and its use to treat or prevent cholesterol-related diseases.
AR061171A1 (en) PROTEINS OF UNION TO THE GROWTH FACTOR OF HEPATOCITS (FCH)
BRPI0717845A2 (en) Use of compounds, pharmaceutical compositions and methods for the treatment and / or prophylaxis of diseases that can be treated with HDL-cholesterol elevating agents and compounds.
CL2008001756A1 (en) Interference RNA Agent (IARN); pharmaceutical composition comprising it; and its use to treat pathological processes mediated at least in part by the expression of the epithelial sodium channel alpha (alpha-enac)
MX2008016453A (en) COMPOSITIONS AND METHODS TO TREAT PARASITE INFECTIONS.
AR061170A1 (en) PROTEINS THAT JOIN THE HEPATOCITE GROWTH FACTOR (HGF)
CL2008002782A1 (en) Neutralizing anti-bv8 antibody; composition comprising it; and its use to treat tumors in humans previously treated with a vascular endothelial growth factor antagonist.
CR10730A (en) ANTI NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF DISEASES RELATED TO THE NOTCH3 GENE
CL2011001232A1 (en) Pharmaceutical combination comprising an antibody that specifically recognizes cd38 and at least cytarabine; and its use for cancer treatment
GT200600240A (en) ANTI-TRKB MONOCLONAL ANTIBODIES AND USES OF THE SAME
ECSP11011297A (en) ILL-17 BINDING PROTEINS
CL2011000230A1 (en) Isolated human monoclonal antibody that binds to the tissue factor pathway inhibitor (tfpi); pharmaceutical composition that includes it; use to treat acquired or genetic deficiencies of coagulation, or to shorten bleeding time.
CY1112912T1 (en) MODIFIED ANTIBODIES ANTI-IL-23P19
AR074360A1 (en) MONOCLONAL ANTIBODY OR FRAGMENT OF UNION TO ANTIGEN OF THE SAME PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE SUCH COMPOSITION
CL2011000010A1 (en) Monoclonal anti-beta-amyloid peptide antibody; polynucleotide that encodes it; hybridoma; Method of production; composition comprising it; use to treat diseases related to amyloid proteins; method of diagnosing them; and kit that includes it.
CR9949A (en) 5-LIPOXYGENASE ACTIVATING PROTEIN INHIBITORS (FLAP)
CL2008000935A1 (en) Anti-ige human monoclonal antibody or fragment thereof; nucleic acid encoding it; vector and host cell; Preparation method; pharmaceutical composition that includes it; and its use in the treatment of disorders related to ige.
BRPI0821110B8 (en) anti-nr10/il31ra neutralizing antibody, pharmaceutical composition comprising said antibody and use thereof
GT200800098A (en) ANTI MN ANTIBODIES AND METHODS FOR USE
AR060241A1 (en) COMPOSITIONS AND METHODS OF USE FOR C-MET ANTIBODIES